Niall Martin is on a mission to put DNA repair on the map. He has already gone pretty far along the way to doing this, as the leader of the team that developed the blockbuster cancer drug Lynparza. He is now seeking to repeat this early success at Artios, where he is CEO. Martin talked to Labiotech EU about his experiences and explained why it’s important to plan ahead, protect your technology and not to sell out too short or too soon.
Niall gives his insights on;
- Why timing is key
- How to attract and keep investors
- To partner or not too partner?
- Leading from the front
- Is DNA damage repair the next big thing?
Read more in Labiotech EU